Drug Profile
Sasanlimab - Pfizer
Alternative Names: Humanized hinge region-stabilized IgG4 monoclonal anti-PD1 antibody - Pfizer; PF-06801591; PF-6801591; RN-888Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor agonists; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer
- Phase II Renal cell carcinoma
- Phase I/II Non-small cell lung cancer; Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Canada (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV)